Oxford Immunotec Ltd - Product Pipeline Analysis, 2019 Update
- GDME6331PD
- Pages: 40
- October 2019
- Total Views:1106
- Region : Europe
- GlobalData
- Equity Research Report
- Details
- Table Of Content
- Licence Rights
- Section Purchase
- Products and Companies
Details
Summary
Oxford Immunotec Ltd (Oxford Immunotec) a subsidiary of Oxford Immunotec Global Plc is a medical device company that offers proprietary tests for immune-regulated conditions. The company offers in vitro diagnostic, T-SPOT CMV Test, C6 Lyme ELISA Test, T-Cell Xtend Reagent. It offers T-SPOT.TB test that diagnoses both latent TB infection and active disease by measuring T cells that have been activated by Mycobacterium tuberculosis antigens. Oxford Immunotec's T-SPOT solution offers diagnosing disease by measuring immune response to an infection. The company offers laboratories services such as oxford diagnostics. It operates in the US, the UK, Japan, South Korea and China. Oxford Immunotec is headquartered in Abingdon, the UK.
This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Oxford Immunotec Ltd
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors' pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
Table Of Content
Scope
Table of Contents
Table of Contents
List of Tables
List of Figures
Oxford Immunotec Ltd Company Overview
Oxford Immunotec Ltd Company Snapshot
Oxford Immunotec Ltd Pipeline Products and Ongoing Clinical Trials Overview
Oxford Immunotec Ltd-Pipeline Analysis Overview
Oxford Immunotec Ltd-Key Facts
Oxford Immunotec Ltd-Major Products and Services
Oxford Immunotec Ltd Pipeline Products by Development Stage
Oxford Immunotec Ltd Ongoing Clinical Trials by Trial Status
Oxford Immunotec Ltd Pipeline Products Overview
B Cell ELISPOT Assay
B Cell ELISPOT Assay Product Overview
ELISPOT Tumor Assay
ELISPOT Tumor Assay Product Overview
ELISPOT Tumor Assay Clinical Trial
I-O Monitoring Test
I-O Monitoring Test Product Overview
Metabovis Assay-Homocysteine
Metabovis Assay-Homocysteine Product Overview
Risk Stratification System-Kidney Transplantation
Risk Stratification System-Kidney Transplantation Product Overview
SpiroFind
SpiroFind Product Overview
Stratokine
Stratokine Product Overview
T-Cell Select
T-Cell Select Product Overview
T-SPOT.ICA
T-SPOT.ICA Product Overview
UREA And T-SPOT Based Diagnostic Assay-Immunological Disease
UREA And T-SPOT Based Diagnostic Assay-Immunological Disease Product Overview
UREA And T-SPOT Based Diagnostic Assay-Infectious Disease
UREA And T-SPOT Based Diagnostic Assay-Infectious Disease Product Overview
Oxford Immunotec Ltd-Key Competitors
Oxford Immunotec Ltd-Key Employees
Oxford Immunotec Ltd-Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Oxford Immunotec Ltd, Recent Developments
Aug 06, 2019: Oxford Immunotec reports second quarter 2019 financial results
Jun 24, 2019: Oxford Immunotec appoints Patrick J. Balthrop, Sr. as Chairman
May 17, 2019: Oxford Immunotec Welcomes Updated CDC Recommendations for Tuberculosis Screening and Testing of Healthcare Personnel
May 09, 2019: Oxford Immunotec reports first quarter 2019 financial results
Mar 28, 2019: Oxford Immunotec announces new initiative to bring the benefit of modern tuberculosis testing to the Russian Federation
Mar 21, 2019: Oxford Immunotec announces Chief Financial Officer transition
Mar 11, 2019: Oxford Immunotec reports fourth quarter and full year 2018 financial results
Nov 09, 2018: Oxford Immunotec announces third quarter 2018 financial results
Jul 31, 2018: Oxford Immunotec reports second quarter 2018 financial results
Jun 05, 2018: Oxford Immunotec Applauds Updated Guidelines from the American Academy of Pediatrics Supporting Expanded Use of the T-SPOT.TB Test
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer
List Of Figure
List of Figures
Oxford Immunotec Ltd Pipeline Products by Equipment Type
Oxford Immunotec Ltd Pipeline Products by Development Stage
Oxford Immunotec Ltd Ongoing Clinical Trials by Trial Status
List Of Table
List of Tables
Oxford Immunotec Ltd Pipeline Products and Ongoing Clinical Trials Overview
Oxford Immunotec Ltd Pipeline Products by Equipment Type
Oxford Immunotec Ltd Pipeline Products by Indication
Oxford Immunotec Ltd Ongoing Clinical Trials by Trial Status
Oxford Immunotec Ltd, Key Facts
Oxford Immunotec Ltd, Major Products and Services
Oxford Immunotec Ltd Number of Pipeline Products by Development Stage
Oxford Immunotec Ltd Pipeline Products Summary by Development Stage
Oxford Immunotec Ltd Ongoing Clinical Trials by Trial Status
Oxford Immunotec Ltd Ongoing Clinical Trials Summary
B Cell ELISPOT Assay-Product Status
B Cell ELISPOT Assay-Product Description
ELISPOT Tumor Assay-Product Status
ELISPOT Tumor Assay-Product Description
ELISPOT Tumor Assay-da VINci Study (OTSGC-A24 Therapeutic Peptide Vaccine + Ipilimumab + Nivolumab) Nivolumab, Ipilimumab and OTSGC-A24 Therapeutic Peptide Vaccine in Gastric Cancer-A Combination Immunotherapy Phase Ib Study
I-O Monitoring Test-Product Status
I-O Monitoring Test-Product Description
Metabovis Assay-Homocysteine-Product Status
Metabovis Assay-Homocysteine-Product Description
Risk Stratification System-Kidney Transplantation-Product Status
Risk Stratification System-Kidney Transplantation-Product Description
SpiroFind-Product Status
SpiroFind-Product Description
Stratokine-Product Status
Stratokine-Product Description
T-Cell Select-Product Status
T-Cell Select-Product Description
T-SPOT.ICA-Product Status
T-SPOT.ICA-Product Description
UREA And T-SPOT Based Diagnostic Assay-Immunological Disease-Product Status
UREA And T-SPOT Based Diagnostic Assay-Immunological Disease-Product Description
UREA And T-SPOT Based Diagnostic Assay-Infectious Disease-Product Status
UREA And T-SPOT Based Diagnostic Assay-Infectious Disease-Product Description
Oxford Immunotec Ltd, Key Employees
Oxford Immunotec Ltd, Subsidiaries
Glossary
Licence Rights
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
Section Purchase
Products and Companies
Products
Oxford Immunotec Ltd, Product, Pipeline, Product Pipeline, Key Pipeline, Products by Equipment Type, Equipment Type, Therapy Area, Products by Therapy Area, Development Stage, Products by Development Stage, Milestone, Products by Milestone, Major Products, Brands, No of Products, Device Class, Market, Territory, Product Name, Therapy Name, Trial Name, Trial, Indication, Summary, Event Type, Clinical Trial, MileStone, Product Status, Product Description, Description, Patent, Patent Details, Competitors, Key Employees, Subsidiaries, Locations, News, Events, Developments, medical devices, business description, company facts, trial phase, approval, estimated, technology, product patent details, phase, trial status, trial objective, trial design, trial site, business strategies, trends, pipeline and technology, sales strategies
Companies
AorTech International Plc
Arcomedical Infusion Ltd
CME Medical UK Ltd
Summary
Oxford Immunotec Ltd (Oxford Immunotec) a subsidiary of Oxford Immunotec Global Plc is a medical device company that offers proprietary tests for immune-regulated conditions. The company offers in vitro diagnostic, T-SPOT CMV Test, C6 Lyme ELISA Test, T-Cell Xtend Reagent. It offers T-SPOT.TB test that diagnoses both latent TB infection and active disease by measuring T cells that have been activated by Mycobacterium tuberculosis antigens. Oxford Immunotec's T-SPOT solution offers diagnosing disease by measuring immune response to an infection. The company offers laboratories services such as oxford diagnostics. It operates in the US, the UK, Japan, South Korea and China. Oxford Immunotec is headquartered in Abingdon, the UK.
This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Oxford Immunotec Ltd
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors' pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
Scope
Table of Contents
Table of Contents
List of Tables
List of Figures
Oxford Immunotec Ltd Company Overview
Oxford Immunotec Ltd Company Snapshot
Oxford Immunotec Ltd Pipeline Products and Ongoing Clinical Trials Overview
Oxford Immunotec Ltd-Pipeline Analysis Overview
Oxford Immunotec Ltd-Key Facts
Oxford Immunotec Ltd-Major Products and Services
Oxford Immunotec Ltd Pipeline Products by Development Stage
Oxford Immunotec Ltd Ongoing Clinical Trials by Trial Status
Oxford Immunotec Ltd Pipeline Products Overview
B Cell ELISPOT Assay
B Cell ELISPOT Assay Product Overview
ELISPOT Tumor Assay
ELISPOT Tumor Assay Product Overview
ELISPOT Tumor Assay Clinical Trial
I-O Monitoring Test
I-O Monitoring Test Product Overview
Metabovis Assay-Homocysteine
Metabovis Assay-Homocysteine Product Overview
Risk Stratification System-Kidney Transplantation
Risk Stratification System-Kidney Transplantation Product Overview
SpiroFind
SpiroFind Product Overview
Stratokine
Stratokine Product Overview
T-Cell Select
T-Cell Select Product Overview
T-SPOT.ICA
T-SPOT.ICA Product Overview
UREA And T-SPOT Based Diagnostic Assay-Immunological Disease
UREA And T-SPOT Based Diagnostic Assay-Immunological Disease Product Overview
UREA And T-SPOT Based Diagnostic Assay-Infectious Disease
UREA And T-SPOT Based Diagnostic Assay-Infectious Disease Product Overview
Oxford Immunotec Ltd-Key Competitors
Oxford Immunotec Ltd-Key Employees
Oxford Immunotec Ltd-Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Oxford Immunotec Ltd, Recent Developments
Aug 06, 2019: Oxford Immunotec reports second quarter 2019 financial results
Jun 24, 2019: Oxford Immunotec appoints Patrick J. Balthrop, Sr. as Chairman
May 17, 2019: Oxford Immunotec Welcomes Updated CDC Recommendations for Tuberculosis Screening and Testing of Healthcare Personnel
May 09, 2019: Oxford Immunotec reports first quarter 2019 financial results
Mar 28, 2019: Oxford Immunotec announces new initiative to bring the benefit of modern tuberculosis testing to the Russian Federation
Mar 21, 2019: Oxford Immunotec announces Chief Financial Officer transition
Mar 11, 2019: Oxford Immunotec reports fourth quarter and full year 2018 financial results
Nov 09, 2018: Oxford Immunotec announces third quarter 2018 financial results
Jul 31, 2018: Oxford Immunotec reports second quarter 2018 financial results
Jun 05, 2018: Oxford Immunotec Applauds Updated Guidelines from the American Academy of Pediatrics Supporting Expanded Use of the T-SPOT.TB Test
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer
List Of Figure
List of Figures
Oxford Immunotec Ltd Pipeline Products by Equipment Type
Oxford Immunotec Ltd Pipeline Products by Development Stage
Oxford Immunotec Ltd Ongoing Clinical Trials by Trial Status
List Of Table
List of Tables
Oxford Immunotec Ltd Pipeline Products and Ongoing Clinical Trials Overview
Oxford Immunotec Ltd Pipeline Products by Equipment Type
Oxford Immunotec Ltd Pipeline Products by Indication
Oxford Immunotec Ltd Ongoing Clinical Trials by Trial Status
Oxford Immunotec Ltd, Key Facts
Oxford Immunotec Ltd, Major Products and Services
Oxford Immunotec Ltd Number of Pipeline Products by Development Stage
Oxford Immunotec Ltd Pipeline Products Summary by Development Stage
Oxford Immunotec Ltd Ongoing Clinical Trials by Trial Status
Oxford Immunotec Ltd Ongoing Clinical Trials Summary
B Cell ELISPOT Assay-Product Status
B Cell ELISPOT Assay-Product Description
ELISPOT Tumor Assay-Product Status
ELISPOT Tumor Assay-Product Description
ELISPOT Tumor Assay-da VINci Study (OTSGC-A24 Therapeutic Peptide Vaccine + Ipilimumab + Nivolumab) Nivolumab, Ipilimumab and OTSGC-A24 Therapeutic Peptide Vaccine in Gastric Cancer-A Combination Immunotherapy Phase Ib Study
I-O Monitoring Test-Product Status
I-O Monitoring Test-Product Description
Metabovis Assay-Homocysteine-Product Status
Metabovis Assay-Homocysteine-Product Description
Risk Stratification System-Kidney Transplantation-Product Status
Risk Stratification System-Kidney Transplantation-Product Description
SpiroFind-Product Status
SpiroFind-Product Description
Stratokine-Product Status
Stratokine-Product Description
T-Cell Select-Product Status
T-Cell Select-Product Description
T-SPOT.ICA-Product Status
T-SPOT.ICA-Product Description
UREA And T-SPOT Based Diagnostic Assay-Immunological Disease-Product Status
UREA And T-SPOT Based Diagnostic Assay-Immunological Disease-Product Description
UREA And T-SPOT Based Diagnostic Assay-Infectious Disease-Product Status
UREA And T-SPOT Based Diagnostic Assay-Infectious Disease-Product Description
Oxford Immunotec Ltd, Key Employees
Oxford Immunotec Ltd, Subsidiaries
Glossary
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
Products
Oxford Immunotec Ltd, Product, Pipeline, Product Pipeline, Key Pipeline, Products by Equipment Type, Equipment Type, Therapy Area, Products by Therapy Area, Development Stage, Products by Development Stage, Milestone, Products by Milestone, Major Products, Brands, No of Products, Device Class, Market, Territory, Product Name, Therapy Name, Trial Name, Trial, Indication, Summary, Event Type, Clinical Trial, MileStone, Product Status, Product Description, Description, Patent, Patent Details, Competitors, Key Employees, Subsidiaries, Locations, News, Events, Developments, medical devices, business description, company facts, trial phase, approval, estimated, technology, product patent details, phase, trial status, trial objective, trial design, trial site, business strategies, trends, pipeline and technology, sales strategies
Companies
AorTech International Plc
Arcomedical Infusion Ltd
CME Medical UK Ltd
Related Reports
Page 116 | 
January 2020
Page 235 | January 2020
Page 183 | September 2019
Page 244 | August 2019
Page 207 | August 2019